Department of Anesthesiology and Reanimation, Sakarya Training and Research Hospital, Sakarya, Turkey.
Department of Anesthesiology and Reanimation, Sakarya University Faculty of Medicine, Training and Research Hospital, Sakarya, Turkey.
J Korean Med Sci. 2021 Nov 15;36(44):e309. doi: 10.3346/jkms.2021.36.e309.
We assessed maternal and neonatal outcomes of critically ill pregnant and puerperal patients in the clinical course of coronavirus disease 2019 (COVID-19).
Records of pregnant and puerperal women with polymerase chain reaction positive COVID-19 virus who were admitted to our intensive care unit (ICU) from March 2020 to August 2021 were investigated. Demographic, clinical and laboratory data, pharmacotherapy, and neonatal outcomes were analyzed. These outcomes were compared between patients that were discharged from ICU and patients who died in ICU.
Nineteen women were included in this study. Additional oxygen was required in all cases (100%). Eight patients (42%) were intubated and mechanically ventilated. All patients that were mechanically ventilated have died. Increased levels of C-reactive protein (CRP) was seen in all patients (100%). D-dimer values increased in 15 patients (78.9%); interleukin-6 (IL-6) increased in 16 cases (84.2%). Sixteen patients used antiviral drugs. Eleven patients were discharged from the ICU and eight patients have died due to complications of COVID-19 showing an ICU mortality rate of 42.1%. Mean number of hospitalized days in ICU was significantly lower in patients that were discharged ( = 0.037). Seventeen patients underwent cesarean-section (C/S) (89.4%). Mean birth week was significantly lower in patients who died in ICU ( = 0.024). Eleven preterm (57.8%) and eight term deliveries (42.1%) occurred.
High mortality rate was detected among critically ill pregnant/parturient patients followed in the ICU. Main predictors of mortality were the need of invasive mechanical ventilation and higher number of days hospitalized in ICU. Rate of C/S operations and preterm delivery were high. Pleasingly, the rate of neonatal death was low and no neonatal COVID-19 occurred.
我们评估了在 2019 年冠状病毒病(COVID-19)临床病程中患有重症的妊娠和产褥期患者的母婴结局。
调查了 2020 年 3 月至 2021 年 8 月期间因聚合酶链反应阳性 COVID-19 病毒而入住我院重症监护病房(ICU)的妊娠和产褥期妇女的记录。分析了人口统计学、临床和实验室数据、药物治疗和新生儿结局。并比较了从 ICU 出院和在 ICU 死亡的患者之间的这些结局。
本研究共纳入 19 名女性。所有患者均需额外吸氧(100%)。8 名患者(42%)行气管插管和机械通气。所有接受机械通气的患者均死亡。所有患者的 C 反应蛋白(CRP)水平均升高(100%)。15 例患者的 D-二聚体值升高(78.9%);16 例患者白细胞介素-6(IL-6)升高(84.2%)。16 名患者使用抗病毒药物。11 名患者从 ICU 出院,8 名患者因 COVID-19 并发症死亡,ICU 死亡率为 42.1%。从 ICU 出院的患者在 ICU 住院天数明显较少( = 0.037)。17 例行剖宫产术(C/S)(89.4%)。在 ICU 死亡的患者中,出生周数明显较低( = 0.024)。11 例早产(57.8%)和 8 例足月分娩(42.1%)。
在 ICU 随访的重症妊娠/分娩患者中,死亡率较高。死亡的主要预测因素是需要有创机械通气和 ICU 住院天数较多。C/S 手术和早产的发生率较高。令人欣慰的是,新生儿死亡率较低,且未发生新生儿 COVID-19。